TREATMENT OF LIGHT CHAIN (AL) AMYLOIDOSIS WITH BORTEZOMIB AND DEXAMETASONE

被引：0
|
作者：
Canovas, A. [1 ]
Alonso, J. J. [1 ]
Barreiro, G. [1 ]
机构：
[1] Hosp Cruces, Bilbao, Spain
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2008年 / 93卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1108
引用
收藏
页码：435 / 436
页数：2
相关论文
共 50 条
  • [21] Neuropathy and efficacy of once weekly subcutaneous bortezomib in multiple myeloma and light chain (AL) amyloidosis
    Sidana, Surbhi
    Narkhede, Mayur
    Elson, Paul
    Hastings, Debbie
    Faiman, Beth
    Valent, Jason
    Samaras, Christy
    Hamilton, Kimberly
    Liu, Hien K.
    Smith, Mitchell R.
    Reu, Frederic J.
    PLOS ONE, 2017, 12 (03):
  • [22] A Phase I Trial of Pomalidomide, Bortezomib (Velcade), and Dexamethasone (PVD) As Initial Treatment of AL Amyloidosis and Light Chain Deposition Disease
    Zonder, Jeffrey
    Houde, Christiane
    Tuchman, Sascha
    Kukreti, Vishal
    Sanchorawala, Vaishali
    Pregja, Silva
    Reichel, Kathy A.
    Burt, Steven M.
    Neveux, Colleen
    Matous, Jeffrey
    BLOOD, 2014, 124 (21)
  • [23] Safety Profile of Bortezomib Impacts Survival in Light Chain Amyloidosis
    Van de Wyngaert, Zoe
    Vanoutryve, Greg
    Fouquet, Guillemette
    Guidez, Stephanie
    Herbaux, Charles
    Demarquette, Helene
    Renaud, Loic
    Terriou, Louis
    Noel, Marie Pierre
    Petillon, Marie Odile
    Hivert, Benedicte
    Wemeau, Matthieu
    Launay, David
    Lamblin, Nicolas
    Hachulla, Eric
    Facon, Thierry
    Leleu, Xavier
    BLOOD, 2014, 124 (21)
  • [24] TREATMENT OF LIGHT CHAIN AMYLOIDOSIS
    Palladini, G.
    Milani, P.
    HAEMATOLOGICA, 2017, 102 : 201 - 203
  • [25] Bortezomib With or Without Dexamethasone in Primary Systemic (Light Chain) Amyloidosis
    Kastritis, Efstathios
    Wechalekar, Ashutosh D.
    Dimopoulos, Meletios A.
    Merlini, Giampaolo
    Hawkins, Philip N.
    Perfetti, Vittorio
    Gillmore, Julian D.
    Palladini, Giovanni
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (06) : 1031 - 1037
  • [26] Bortezomib with Dexamethasone in Newly Diagnosed Patients with Primary Systemic Light Chain Amyloidosis or Multiple Myeloma-Associated AL Amyloidosis
    Huang, Beihui
    Li, Juan
    Liu, Junru
    Zheng, Dong
    Chen, Mei
    Zhou, Zhenhai
    Xu, Duorong
    Zou, Waiyi
    BLOOD, 2012, 120 (21)
  • [27] Light-chain (AL) amyloidosis for nephrologists-treatment standard
    Anand, Shankara
    O'Neill-Dee, Maggie
    Sanchorawala, Vaishali
    Verma, Ashish
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2024, 40 (01) : 34 - 47
  • [28] Treatment of hepatic amyloid light-chain amyloidosis with bortezomib and dexamethasone in a liver transplant patient
    Nakano, Ryosuke
    Ohira, Masahiro
    Ide, Kentaro
    Ishiyama, Kohei
    Kobayashi, Tsuyoshi
    Tahara, Hiroyuki
    Tashiro, Hirotaka
    Kuroda, Yoshiaki
    Ichinohe, Tatsuo
    Arihiro, Koji
    Chayama, Kazuaki
    Ohdan, Hideki
    HEPATOLOGY RESEARCH, 2015, 45 (10) : E150 - E155
  • [29] Treatment with Bortezomib (Bor) Based Therapy Followed By Autologous Stem Cell Transplantation (SCT) Improves Outcomes in Light Chain Amyloidosis (AL)
    Jain, Tania
    Kung, Shu Ting
    Shah, Vishal
    Dueck, Amylou Constance
    Kosiorek, Heidi E.
    Mikhael, Joseph
    Bergsagel, P. Leif
    Reeder, Craig B.
    Noel, Pierre
    Adams, Roberta H.
    Luft, Susan
    Mayo, Angela
    Stewart, A. Keith
    Fonseca, Rafael
    BLOOD, 2016, 128 (22)
  • [30] Survival with bortezomib in light chain cardiac amyloidosis: a boon that lessens the gloom
    Singh, A.
    Laubach, J. P.
    Geller, H. I.
    Mirto, T.
    Dupee, D.
    Falk, R. H.
    EUROPEAN HEART JOURNAL, 2016, 37 : 569 - 569
12345